Moreover, in other studies, perampanel, an FDA-approved non-competitive AMPA receptor antagonist to manage epilepsy, has prevented ALS-like progressive motor dysfunction in conditional ADAR2 knockout mice and increased the cortical excitability threshold [143,144]. Here, ADARB1 is linked to amyotrophic lateral sclerosis.